Title : Randomized, Double-Blind, Phase II Study of Ruxolitinib or Placebo in Combination With Capecitabine in Patients With Metastatic Pancreatic Cancer for Whom Therapy With Gemcitabine Has Failed.

Pub. Date : 2015 Dec 1

PMID : 26351344






1 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 In a prespecified subgroup analysis of patients with inflammation, defined by serum C-reactive protein levels greater than the study population median (ie, 13 mg/L), OS was significantly greater with ruxolitinib than with placebo (hazard ratio, 0.47; 95% CI, 0.26 to 0.85; P = .011). ruxolitinib C-reactive protein Homo sapiens